Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Amortization of Deferred Charges (2016)

Historic Amortization of Deferred Charges for Ekso Bionics Holdings (EKSO) over the last 4 years, with Q4 2016 value amounting to -$9000.0.

  • Ekso Bionics Holdings' Amortization of Deferred Charges changed 0.0% to -$9000.0 in Q4 2016 from the same period last year, while for Dec 2016 it was -$36000.0, marking a year-over-year increase of 270.27%. This contributed to the annual value of -$36000.0 for FY2016, which is 270.27% up from last year.
  • According to the latest figures from Q4 2016, Ekso Bionics Holdings' Amortization of Deferred Charges is -$9000.0, which was down 0.0% from -$9000.0 recorded in Q3 2016.
  • In the past 5 years, Ekso Bionics Holdings' Amortization of Deferred Charges registered a high of -$9000.0 during Q2 2015, and its lowest value of -$18104.0 during Q2 2013.
  • Over the past 4 years, Ekso Bionics Holdings' median Amortization of Deferred Charges value was -$9000.0 (recorded in 2015), while the average stood at -$9855.0.
  • As far as peak fluctuations go, Ekso Bionics Holdings' Amortization of Deferred Charges surged by 5000.0% in 2014, and later plummeted by 1047.28% in 2015.
  • Quarter analysis of 4 years shows Ekso Bionics Holdings' Amortization of Deferred Charges stood at -$18104.0 in 2013, then surged by 50.0% to -$9052.0 in 2014, then grew by 0.57% to -$9000.0 in 2015, then changed by 0.0% to -$9000.0 in 2016.
  • Its Amortization of Deferred Charges was -$9000.0 in Q4 2016, compared to -$9000.0 in Q3 2016 and -$9000.0 in Q2 2016.